Oncology

Novocure’s TTFields device slows metastasis in NSCLC

Novocure’s Tumor Treating Fields (TTFields) therapy met its primary endpoint in the Phase III METIS trial by slowing the progression…

Iambic begins dosing in trial of IAM1363 for HER2-driven cancer

Iambic Therapeutics has initiated the dosing of the first subject in its Phase I/Ib clinical trial of IAM1363, a novel…

Immuneering doses first subject in Phase I/IIa solid tumour trial

Immuneering has dosed the first subject in its Phase I/IIa clinical trial of IMM-6-415 for the treatment of advanced solid…

Regeneron hit with FDA rejection for blood cancer therapy

The US Food and Drug Administration (FDA) has rejected Regeneron Pharmaceutical’s approval application for odronextamab in two forms of lymphoma,…

Edgewood secures $20m in Series A for clinical development of cancer therapy

Massachusetts-based company Edgewood Oncology has raised $20m in Series A to advance the clinical development of its lead cancer therapy…

Ovarian cancer: four drug trials to watch

Most patients with ovarian cancer are diagnosed at late stage as symptoms at early stages are minimal making it difficult…

Innate shelves lacutamab monotherapy plans in peripheral T cell lymphoma

Innate has dropped plans to evaluate lacutamab as a monotherapy in KIR3DL2-expressing refractory/relapsing peripheral T cell lymphoma (r/r PTCL) following…

AstraZeneca’s Tagrisso regimen shows benefit in NSCLC trial

UK-based pharmaceutical company AstraZeneca has reported that the FLAURA2 Phase III clinical trial of Tagrisso (osimertinib) combined with chemotherapy showed…

Nouscom extends Series C round to $82m for cancer vaccine trials

Immuno-oncology company Nouscom has extended a Series C financing round to raise $82m (€75.8m) as it looks to advance its…

Molecular glues are the latest craze in pharma research, but what are they?

February’s announcement that Novo Nordisk was partnering with a biotech developing molecular glues to treat rare diseases was the latest…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close